Oncopeptides is a pharmaceutical company developing targeted therapies for difficult-to-treat hematological cancers. The company is focusing on the development of melflufen, a novel lipophilic peptide conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Cytotoxics. Melflufen is in development as a new treatment for multiple myeloma, including the Phase 2 pivotal trial HORIZON currently underway and a global confirmatory Phase 3 trial (OCEAN) continuing enrollment.